SUN-181 Case Report: Rare Complication of SGLT2 Inhibitors Can Occur Only 10 Days after Starting the Medication
Abstract
Abstract Introduction: Fournier’s gangrene is an extremely rare infection that can occur in diabetic patients. The FDA recently issued a warning about patients taking sodium-glucose cotransporter-2 inhibitors stating that these patients are liable to develop Fournier gangrene. This complication usually occurs few months after starting the medication. Up to our knowledge, total 12 cases have been reported in literature from May 2013 to May 2018. We report another case of Fournier gangrene associated with the use of empagliflozin, however our case is unique as the presentation was only 10 days after starting the medication. Case report:We present a 57 years old Caucasian male with past medical history of uncontrolled type 2 diabetes diagnosed around 10 years ago and complicated by peripheral neuropathy, hashimoto’s hypothyroidism and morbid obesity who was following as outpatient with an endocrinologist. His hemoglobin A1C has been uncontrolled despite being on glipizide 10 mg BID, metformin 1gm BID and linagliptin 5mg daily so decision was made to start empagliflozin. After 10 days, patient complained of severe left groin pain for which he was initially treated as cellulitis in an outpatient facility however no improvement was noticed. He went to the ED. On physical examination, his weight 192 kilograms with BMI of 62.76kg/m2, he was afebrile and vitally stable. Perineal examination revealed a grossly swollen and indurated right scrotum with tender spermatic cord, epididymis…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 7 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.